Varlitinib | ARRY-543 | CAS#845272-21-1

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Varlitinib

MedKoo Code#: 205660
Name: Varlitinib
CAS#: 1146629-86-8 (Varlitinib tosylate), 845272-21-1 (Varlitinib) Synonym: code name: AR 00334543; ARRY 543. 4,6-Quinazolinediamine, N4-[3-chloro-4-(2-thiazolylmethoxy)phenyl]-N6-[(4R)-4,5-dihydro-4-methyl-2-oxazolyl]-, 4-methylbenzenesulfonate (1:2). 　 IUPAC/Chemical name: (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine.
Chemical structure	Theoretical analysis
	Varlitinib Chemical Formula: C22H19ClN6O2S Exact Mass: 466.09787 Molecular Weight: 466.94 Elemental Analysis: C, 56.59; H, 4.10; Cl, 7.59; N, 18.00; O, 6.85; S, 6.87 Varlitinib ditosylate. Chemical Formula: C36H35ClN6O8S3 Exact Mass: 810.13670 Molecular Weight: 811.35 Elemental Analysis: C, 53.29; H, 4.35; Cl, 4.37; N, 10.36; O, 15.78; S, 11.86
Availability and price: This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Information about this agent

ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members. ARRY-543 showed benefit in preclinical tumor models that signal through multiple ErbB family members, as well as its efficacy in preclinical models when compared to, and combined with, Herceptin (trastuzumab), Xeloda (capecitabine) and Taxotere (docetaxel) – widely used treatments for solid tumors.

Current developer: Array BioPharma.

References

1. Wallace, Eli et al, Preparation of aminoquinazolines as receptor tyrosine kinase inhibitors, U.S. Pat. Appl. Publ., 20050043334, 24 Feb 2005.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)